Balanced news tone
News Sentiment
NERV sentiment intelligence
Minerva Neurosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-7.5% over one week, +4.7% over four weeks, trend inactive, and near fair-value range.
FEDERATED HERMES, INC. Acquires Additional Shares in Minerva Neurosciences Inc
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Pr
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 21 Oct 2025 07:00
- Source
- Market source
Minerva Neurosci (NERV) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 00:36
- Source
- Stock Titan
FDA hands Minerva Neurosciences refusal to file letter for its roluperidone NDA for schizophrenia
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Oct 2022 07:00
- Source
- drugdiscoverytrends.com
Minerva Neurosciences (NERV) Stock Price, News & Analysis $NERV
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Aug 2016 02:11
- Source
- MarketBeat